Neoadjuvant Chemoradiotherapy Improves Long-Term OS in Pancreatic Cancer
Neoadjuvant chemoradiotherapy improves overall survival (OS), compared with upfront surgery, in patients with resectable or borderline resectable pancreatic cancer, updated data suggest.1 The 5-year OS rate was 14% higher among patients treated with neoadjuvant chemoradiotherapy…